282 related articles for article (PubMed ID: 31437521)
21. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma.
Liang L; Williams MD; Bell D
Head Neck Pathol; 2019 Dec; 13(4):529-534. PubMed ID: 30390196
[TBL] [Abstract][Full Text] [Related]
22. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Chatzopoulos K; Collins AR; Sotiriou S; Keeney MG; Visscher DW; Rivera M; Schembri-Wismayer DJ; Lewis JE; Greipp PT; Sukov WR; Chintakuntlawar AV; Price KA; Garcia JJ
Head Neck Pathol; 2020 Dec; 14(4):951-965. PubMed ID: 32350809
[TBL] [Abstract][Full Text] [Related]
23. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
[TBL] [Abstract][Full Text] [Related]
24. HER2/HER3-positive metastatic salivary duct carcinoma in the pleural effusion: A case report.
Murata K; Kawahara A; Ono T; Takase Y; Abe H; Naito Y; Akiba J
Diagn Cytopathol; 2018 May; 46(5):429-433. PubMed ID: 29205961
[TBL] [Abstract][Full Text] [Related]
25. Primary and Secondary/ Metastatic Salivary Duct Carcinoma Presenting within the Sinonasal Tract.
Agaimy A; Mueller SK; Bishop JA; Chiosea SI
Head Neck Pathol; 2021 Sep; 15(3):769-779. PubMed ID: 33428064
[TBL] [Abstract][Full Text] [Related]
26. PIK3CA mutations and PTEN loss in salivary duct carcinomas.
Griffith CC; Seethala RR; Luvison A; Miller M; Chiosea SI
Am J Surg Pathol; 2013 Aug; 37(8):1201-7. PubMed ID: 23851329
[TBL] [Abstract][Full Text] [Related]
27. Low-grade Apocrine Intraductal Carcinoma: Expanding the Morphologic and Molecular Spectrum of an Enigmatic Salivary Gland Tumor.
Bishop JA; Gagan J; Krane JF; Jo VY
Head Neck Pathol; 2020 Dec; 14(4):869-875. PubMed ID: 31989433
[TBL] [Abstract][Full Text] [Related]
28. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
Yang RK; Zhao P; Lu C; Luo J; Hu R
Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma.
van Boxtel W; Uijen MJM; Verhaegh GW; Willems SM; Jonker MA; ; Schalken JA; van Engen-van Grunsven ICH; van Herpen CML
Oral Oncol; 2020 Nov; 110():105018. PubMed ID: 33039794
[TBL] [Abstract][Full Text] [Related]
30. Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study.
Jalaly JB; Sanati S; Chernock RD; Dibe DG; El-Mofty SK
Head Neck Pathol; 2018 Dec; 12(4):488-492. PubMed ID: 29302899
[TBL] [Abstract][Full Text] [Related]
31. Salivary duct carcinoma cytologically diagnosed distinctly from salivary gland carcinomas with squamous differentiation.
Kawahara A; Harada H; Akiba J; Kage M
Diagn Cytopathol; 2008 Jul; 36(7):485-93. PubMed ID: 18528886
[TBL] [Abstract][Full Text] [Related]
32. ALK Rearrangements Characterize 2 Distinct Types of Salivary Gland Carcinomas: Clinicopathologic and Molecular Analysis of 4 Cases and Literature Review.
Agaimy A; Baněčková M; Ihrler S; Mueller SK; Franchi A; Hartmann A; Stoehr R; Skálová A
Am J Surg Pathol; 2021 Sep; 45(9):1166-1178. PubMed ID: 33871952
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
[TBL] [Abstract][Full Text] [Related]
34. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
[TBL] [Abstract][Full Text] [Related]
35. [Salivary duct carcinoma].
Hungermann D; Roeser K; Buerger H; Jäkel T; Löning T; Herbst H
Pathologe; 2005 Sep; 26(5):353-8. PubMed ID: 16041504
[TBL] [Abstract][Full Text] [Related]
36. An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions.
Bahrami A; Perez-Ordonez B; Dalton JD; Weinreb I
Histopathology; 2013 Aug; 63(2):250-62. PubMed ID: 23738717
[TBL] [Abstract][Full Text] [Related]
37. Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression.
Skálová A; Stárek ; Kucerová V; Szépe P; Plank L
Pathol Res Pract; 2001; 197(9):621-6. PubMed ID: 11569926
[TBL] [Abstract][Full Text] [Related]
38. Sarcomatoid variant of salivary duct carcinoma: clinicopathologic and immunohistochemical study of eight cases with review of the literature.
Nagao T; Gaffey TA; Serizawa H; Iwaya K; Watanabe A; Yoshida T; Yamazaki K; Sageshima M; Lewis JE
Am J Clin Pathol; 2004 Aug; 122(2):222-31. PubMed ID: 15323139
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland.
Al-Qahtani KH; Tunio MA; Bayoumi Y; Gurusamy VM; Bahamdain FA; Fatani H
J Otolaryngol Head Neck Surg; 2016 May; 45(1):32. PubMed ID: 27184361
[TBL] [Abstract][Full Text] [Related]
40. [Salivary duct carcinoma--a clinicopathological analysis of five cases].
Bień S; Sygut J; Kopczyński J; Postuła S; Ziółkowska M
Otolaryngol Pol; 2007; 61(1):33-8. PubMed ID: 17605416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
